Avistone Announces Results from Two Sponsored Clinical Research Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Avistone Biotechnology Announces Closing of Series B Financing
Beijing-based Avistone Biotechnology has raised 1 billion yuan, about $140 million, to bankroll commercialization of its recently approved lung cancer drug in China and run trials of other assets.